Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer.

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 27136744)

Published in Sci Rep on May 03, 2016

Authors

Nai-Jung Chiang¹^,2^,3, Chiun Hsu⁴^,5, Jen-Shi Chen⁶, Hsiao-Hui Tsou⁷^,8, Ying-Ying Shen⁹, Yee Chao¹⁰, Ming-Huang Chen¹⁰, Ta-Sen Yeh¹¹, Yan-Shen Shan¹^,12, Shiu-Feng Huang⁹, Li-Tzong Chen²^,3^,13^,14

Author Affiliations

1: Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
2: National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
3: Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
4: Department of Oncology, National Taiwan University Hospital, and National Taiwan University Cancer Center, Taipei, Taiwan.
5: Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.
6: Division of Hematology and Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan.
7: Division of Biostatistics and Bioinformatics, Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan.
8: Graduate Institute of Biostatistics, College of Public Health, China Medical University, Taichung, Taiwan.
9: Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli, Taiwan.
10: Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
11: Department of Surgery, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan.
12: Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan.
13: Institute of Clinical Pharmacology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
14: Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

Articles cited by this ↗

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med (2010) 15.71

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23

Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94

ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol (2011) 8.66

Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol (2011) 5.06

Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One (2011) 3.10

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 2.89

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer (2010) 2.82

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology (2011) 2.63

Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol (2014) 2.32

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol (2008) 2.28

Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet (2013) 2.15

Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res (2014) 1.59

Randomized phase II trial designs with biomarkers. J Clin Oncol (2012) 1.26

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation. BMC Cancer (2013) 1.26

Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS One (2013) 1.21

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One (2013) 1.17

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer (2011) 1.09

Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer (2009) 1.08

Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. Proc Natl Acad Sci U S A (2013) 1.04

ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms. Ann Surg Oncol (2012) 1.03

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Ann Oncol (2015) 1.00

Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review. Cancer Res Treat (2015) 0.90

Clinical and pathological significance of ROS1 expression in intrahepatic cholangiocarcinoma. BMC Cancer (2015) 0.84

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. Clin Lung Cancer (2015) 0.80

ROS1 amplification mediates resistance to gefitinib in glioblastoma cells. Oncotarget (2015) 0.78

Zykadia (Ceritinib) Approved for Patients with Crizotinib-Resistant ALK -Positive Non-Small-Cell Lung Cancer. Am Health Drug Benefits (2015) 0.77

Articles by these authors ⇆

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (2017) 1.38

Diagnostic FDG and FDOPA positron emission tomography scans distinguish the genomic type and treatment outcome of neuroblastoma. Oncotarget (2016) 0.79

Pharmacogenomics study on cadherin 2 network with regard to HIV infection and methadone treatment outcome. PLoS One (2017) 0.75

Upregulation of CISD2 augments ROS homeostasis and contributes to tumorigenesis and poor prognosis of lung adenocarcinoma. Sci Rep (2017) 0.75